My­ovant’s re­l­u­golix wins a piv­otal prostate can­cer show­down with an old stan­dard — com­ing down to the wire on ap­provals

My­ovant $MY­OV has round­ed the fi­nal turn in its de­vel­op­ment race to get re­l­u­golix down to the reg­u­la­to­ry wire at the FDA. And the biotech joined the vir­tu­al crowd at AS­CO with the kind of da­ta need­ed to keep the in­vestor crowd’s at­ten­tion.

Much of the at­ten­tion on the drug has been fo­cused on uter­ine fi­broids, where Ab­b­Vie just scored a reg­u­la­to­ry win for their ri­val drug Ori­ahnn (elagolix) as the biotech post­ed re­sults in prostate can­cer at the AS­CO meet­ing.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN